Antithrombotics (B01) and Antihemorrhagics (B02)
First published: 28 May 2020
Abstract
The article contains sections titled:
1 | Introduction |
2 | B Blood and Blood-Forming Organs, B01 Antithrombotics |
2.1 | B01AA Vitamin K Antagonists |
2.2 | B01AB Heparin Group |
2.3 | B01AC Platelet Aggregation Inhibitors excl. Heparins |
2.4 | B01AD Enzymes |
2.5 | B01AE Direct Thrombin inhibitors |
2.6 | B01AF Direct Factor Xa Inhibitors |
2.7 | B01AX Other Antithrombotic Agents |
3 | B Blood and Blood-Forming Organs, B02 Antihemorrhagics |
3.1 | B02A Antifibrinolytics |
3.1.1 | B02AA Amino Acids |
3.1.2 | B02AB Proteinase Inhibitors |
3.2 | B02B Vitamin K and Other Hemostatics |
3.2.1 | B02BA Vitamin K |
3.2.2 | B02BB Fibrinogen |
3.2.3 | B02BC Local Hemostatics |
3.2.4 | B02BX Other Systemic Hemostatics |
List of Abbreviations | |
References |
References
- 1Farrugia, A. and Cassar, J. (2012) Blood Transfus. 10 (3), 273–278.
- 2Palta, S., et al. (2014) Ind. J. Anaesth. 58 (5), 515–523.
- 3Smith, S. (2009) J. Vet. Emerg. Crit. Care 19 (3), 3–10.
- 4Felgin, V., et al. (2003) Lancet Neurol. 2, 43–53.
- 5Longo, D., et al. (2011) Harrison's Principles of Internal Medicine, 18th edn, McGraw-Hill, New York.
- 6Rao, P., et al. (2017) Blood Rev. 31, 205–211.
- 7Zacconi, T.C., (2018) Intechopen, DOI: 10.5772/Intechopen.76518
- 8Hall, R., et al. (2011) Anesth. Analg. 112 (2), 292–318.
- 9Moncada, S., et al. (1976) Nature 263 (5579), 663–665.
- 10Gremmel, T., et al. (2018) Res. Pract. Thromb. Haemost. 2, 439–449.
- 11George, S., et al. (2019) Clin. Drug Investig. 39, 495–502.
- 12Dagar, V.K. and YP, A.K. (2017) Bioengineered 8 (4), 331–358.
- 13Fan, P., et al. (2018) J. Thorac. Dis. 10 (3), 2011–2015.
- 14Johnson, S.S., et al. (2011) J. Occup. Environ. Med. 53, 2–7.
- 15Ghareep, H. and Karaman, R. (2015) Commonly Used Drugs, Chap. 6, Nova Science Publishers.
- 16Benett, B.L. (2011) Wilderness Environ. Med. 28, 539–549.
- 17Galanakis, I., et al. (2011) Rev. Urol. 13 (3), 131.
- 18Scarano, A., et al. (2013) Int. J. Immunopathol. Pharmacol. 26 (4), 847–854.
- 19Grand View Research Market Report February (2019).
- 20Ghanima, W., et al. (2018) Haematologica 104 (6), 1112.
- 21Erickson-Miller, C.I., et al. (2009) Stem Cells 27, 424–430.
- 22Nilles, K.M., et al. (2019) Hematol. Commun. 3 (11), 1423.
- 23Al-Samkari, H., et al. (2019) Ther. Adv. Hematol. 10, 1–13.
- 24Bussel, J., et al. (2018) Am. J. Hematol. 93 (7), 921–930.
- 25Connell, N.T. and Berliner, N. (2019) Blood 133 (19), 2027–2030.
- 26Kresge, N., et al. (2005) J. Biol. Chem. 280 (8), e5.
- 27Naisbitt, D.J., et al. (2005) J. Pharmacol. Exp. Ther. 313 (3), 1058–6529.
- 28 Wisconsin Alumni Research, US 2427578 (16.9.1947; prior. 2.4.1945).
- 29 Wisconsin Alumni Research, US 3077481 (12.2.1963; appl. 21.2.1961).
- 30 Hoffmann-La Roche, (1955) US 2701804 (CH-prior. 1952).
- 31 Wisconsin Alumni Research, US 3239529 (8.3.1966; appl. 1.3.1962).
- 32Ivanov, I.C., et al. (1990) Arch. Pharm. Ber. Dtsch. Pharm. Ges. (APBDAJ) 323, 521.
- 33 Geigy, (1953) US 2648682 (CH-prior. 1950).
- 34 Spójené farmaceutické Zovody, (1949) US 2482510.
- 35Lund, E. (1957) Acta Med Scand. 157 (1), 39–41.
- 36 Upjohn, (1954) US 2672483 (prior. 1951).
- 37 Lipha, US 3574234 (6.4.1971; F-prior. 13.12.1966, 13.11.1967).
- 38Mentre, F., et al. (1998) Clin. Pharmacol. Ther. 63 (1), 64–78.
- 39Hind, H.G. (1963) Manuf. Chem. (MACSAS) 34, 510.
- 40 Southern California Gland Co., US 2884358 (28.4.1959; appl. 22.4.1957).
- 41 Uclaf, US 2989438 (20.6.1961; appl. 29.12.1958).
- 42Menache, D., et al. (1992) Transfusion 32 (6), 580–588.
- 43Adiguzel, C., et al. (2009) Clin. Appl. Thromb. Hemost. 15 (6), 645–651.
- 44Lindahl, U., et al. (1979) Proc. Natl. Acad. Sci. USA (PNASA6) 76, 3198.
- 45Kabi, A.B., US 4303651 (1.12.1981; appl. 4.1.1980; S-prior. 8.1.1979).
- 46 Rhône-Poulenc Rorer, US 5389618 (14.2.1995; F-prior. 26.6.1990).
- 47Shafiq, N., et al. (2006) Pharmacology 78 (3), 136–143.
- 48Maugeri, N., et al. (2007) Thromb. Haemost. 97 (6), 965–973.
- 49Yusuf, S., et al. (2005) JAMA 293 (4), 427–435.
- 50 Akzo, EP 66908 (15.12.1982; appl. 7.5.1982; NL-prior. 21.5.1981).
- 51 Akzo, US 4438108 (20.3.1984; appl. 12.5.1982; NL-prior. 21.5.1981).
- 52Friedel, H.A., et al. (1994) Drugs 48 (4), 638–640.
- 53Cosmi, B., et al. (2003) Thromb. Res. 109 (5), 333–339.
- 54 Opocrin, EP1833492 (19.9.2007; appl. 27.10.2005).
- 55Chapman, T.A., et al. (2003) Drugs 63 (21), 2357–2377.
- 56Rüdiger, R. (1999) Dtsch. Artztebl. 96 (44), A-2840.
- 57Caprino, L., et al. (1977) Haemostasis 6 (5), 310–317.
- 58 Fidia, US 4296039 (20.10.1981; I-prior. 17.11.1977).
- 59Weizmann, C., Bergmann, E. and Sulzbacher, M. (1950) J. Org. Chem. (JOCEAH) 15, 918.
- 60Selleri, R., et al. (1971) Chim. Ther. (CHTPBA) 6, 203.
- 61 Manetti Roberts, FR 2100850 (appl. 30.6.1971; I-prior. 1.7.1970).
- 62 Sanofi, US 4847265 (11.7.1989; F-prior. 17.2.1987, 27.11.1987).
- 63 Elf Sanofi, EP 281459 (appl. 16.2.1988; F-prior. 17.2.1987).
- 64 Sanofi, WO 9839322 (appl. 5.3.1998; F-prior. 5.3.1997).
- 65Garcia, M.J. and Azerad, R. (1997) Tetrahedron: Asymmetry (TASYE3) 8 (1), 85.
- 66 Centre Etud. Ind. Pharm., DE 2404308 (prior. 30.1.1974).
- 67 Centre Etud. Ind. Pharm., US 4051141 (27.9.1977; F-prior. 1.2.1973).
- 68Maffrand, J.P. and Eloy, F. (1974) Eur. J. Med. Chem. (EJMCA5) 9, 483.
- 69Ullmanns Encykl. Tech. Chem., 3. Aufl., Vol. 13, 90.
- 70 Norwich Pharmacal, US 3235583 (15.2.1966; appl. 22.7.1964).
- 71 Thomae, DE 1116676 (appl. 1955).
- 72 Thomae, GB 807826 (appl. 1956; D-prior. 1955).
- 73 Thomae, US 3031450 (24.4.1962; D-prior. 1959).
- 74Parrott, E.L. (1962) J. Pharm. Sci. (JPMSAE) 51, 897.
- 75 Lee Labs., US 2003374 (1935; appl. 1932).
- 76Corey, E.J., et al. (1976) J. Am. Chem. Soc. (JACSAT) 99, 2006.
- 77Nicolaou, K.C., et al. (1977) Lancet (LANCAO) 1058.
- 78 Burroughs Wellcome, US 4539333 (3.9.1985; GB-prior. 11.5.1976, 17.8.1976, 3.9.1976).
- 79 Burroughs Wellcome, US 4883812 (28.11.1989; GB-prior. 17.8.1976, 3.9.1976).
- 80Nannini, G., et al. (1973) Arzneim.-Forsch. (ARZNAD) 23, 1090.
- 81 Carlo Erba, US 4118504 (3.10.1978; I-prior. 10.11.1970).
- 82Skuballa, W. and Vorbrueggen, H. (1981) Angew. Chem. (ANCEAD) 93 (12), 1080.
- 83 Schering AG, DE 2845770 (D-prior. 19.10.1978).
- 84 Schering AG, DE 3839155 (D-prior. 17.11.1988).
- 85Schrader, B.J., et al. (1990) Clin. Pharm. 9 (2), 118–124.
- 86Knight, D.M., et al. (1995) Mol. Immunol. (MOIMD5) 32, 1271.
- 87Gold, H.K., et al. (1989) Circulation Suppl. (CISUAQ) 80 (4) Abst.), 1063.
- 88 Centocor, WO 9512412 (11.5.1995; USA-prior. 5.11.1993).
- 89 Bristol Myers Co., US 3932407 (13.1.1976; USA-prior. 4.2.1972).
- 90 Bristol Myers Co., US 4208521 (17.6.1980; USA-prior. 31.7.1978).
- 91Cummings, A.J., et al. (1963) J. Pharm. Pharmacol. (JPPMAB) 15, 56.
- 92 COR Therap., WO 9015620 (appl. 15.6.1990; USA-prior. 20.2.1990).
- 93Scarborough, R.M., et al. (1993) J. Biol. Chem. (JBCHA3) 268, 1066–1073.
- 94Egbertson, M.S., et al. (1994) J. Med. Chem. (JMCMAR) 37, 2537.
- 95 Merck & Co., US 5292756 (8.3.1994; USA-prior. 27.9.1990, 30.8.1991).
- 96Murdioch, D., et al. (2006) Drugs 66 (5), 671–692.
- 97 Expermed, WO2015051811 (16.4.2015; appl. 10.10.2013).
- 98Melian, E.B., et al. (2002) Drugs 62 (1), 107–133.
- 99 United Therapeutics Corp., US 6441245 (27.8.2002; USA-prior. 24.10.1997).
- 100 Ube Ind., EP 542411 (12.8.1998; J-prior. 9.9.1991).
- 101 Teva Pharma., US 20020099213 (25.7.2002; USA-prior. 20.3.2001).
- 102Springthorpe, B., et al. (2007) Bioorg. Med. Chem. Lett. 17, 6013–6018.
- 103 AstraZeneca, US 6251910 (26.6.2001; appl. 21.9.1998; SE-prior. 22.7.1997).
- 104 Fisons PLC, WO 9418216 (18.8.1994; appl. 8.2.1994; GB-prior. 10.2.1993).
- 105 Medicines Co., US 8759316 (24.6.2014; appl. 28.6.2013; USA-prior. 10.11.2010).
- 106Chackalamannil, S., et al. (2008) J. Med. Chem. 51, 3061–3064.
- 107 Schering Corp., US 6326380 (4.12.2001; appl. 7.4.2000; USA-prior. 25.11.1997).
- 108Asaki, T., et al. (2015) J. Med. Chem. 58 (18), 7128–7137.
- 109 Nippon Shinyaku, US 7205302 (27.5.2004; appl. 23.10.2003; JP-prior. 26.4.2001).
- 110 Merck & Co., (1954) US 2666729 (appl. 1951).
- 111 American Cyanamid, US 2701227 (1955; appl. 1951).
- 112 Behringwerke, US 3063913 (13.11.1962; D-prior. 29.12.1959).
- 113Mc Cartney, P. (2019) JAMA 321, 56–68.
- 114Hannaford, P., et al. (1995) Br. J. Gen. Pract. 45 (393), 175–179.
- 115Sobel, G.W., et al. (1952) Am. J. Physiol. (AJPHAP) 171, 768.
- 116 Ortho (1960) US 2961382 (appl. 1957).
- 117 Parke Davis, (1953) US 2624691 (appl. 1946).
- 118 Ortho Pharmaceutical, US 3136703 (9.6.1964; prior. 1.10.1957, 22.4.1958).
- 119 Cutter Labs., US 3234106 (8.2.1966; appl. 3.12.1962).
- 120Frisch, E.P. (1972) J. Clin. Pathol. 25 (7), 654–655.
- 121 Boehringer Mannheim, CA2107476 (17.10.1992; USA-prior. 16.4.1991).
- 122Moser, M., et al. (1999) Exp. Opin. Investig. Drugs 8 (3), 329–335.
- 123Hennerici, M.G., et al. (2006) Lancet 368 (9550), 1871–1878.
- 124 Lilly, E., CA2139468 (6.7.1995; USA-prior. 5.1.1994).
- 125Parsons, M., et al. (2012) New Engl. J. Med. 399 (12), 1099–1107.
- 126 Genentech, CA1341432 (17.6.2003; USA-prior. 20.5.1988).
- 127Esmon, C.T., et al. (1987) Adv. Exp. Med. Biol. 214, 47–54.
- 128Matheson, A.J. and Goa, K.L. (2000) Drugs 60 (3), 679–700.
- 129Lubenow, N., et al. (2005) J. Thromb. Haemostat. 3 (11), 2428–2436.
- 130 Mitsubishi Chem. Ind., EP 8746 (11.8.1982; appl. 22.8.1979; USA-prior. 31.8.1978).
- 131 Mitsubishi Chem. Corp., US 5925760 (20.7.1999; appl. 13.3.1992; J-prior. 7.8.1996).
- 132Gustafsson, D., et al. (1998) Thromb. Haemost. 79, 110–118.
- 133Gustafsson, D., et al. (2004) Nat. Rev. Drug Discovery (NRDDAG) 3, 649.
- 134Seebach, D., et al. (1990) Liebigs Ann. Chem. (LACHDL) 687.
10.1002/jlac.1990199001129 Google Scholar
- 135 Astra, WO 9723499 (3.7.1997; appl. 17.12.1996; GB-prior. 21.12.1995).
- 136Okayama, T., et al. (1996) Chem. Pharm. Bull. (CPBTAL) 44 (7), 1344–1350.
- 137 Biogen, US 5196404 (23.3.1993; appl. 6.7.1990; USA-prior. 18.8.1989).
- 138 Novetide, WO 20070033383 (22.3.2007; appl. 14.9.2006; USA-prior. 14.9.2005).
- 139Hanel, N., et al. (2002) J. Med. Chem. (JMCMAR) 45, 1757–1766.
- 140 Boehringer Ingelheim, WO 9837075 (27.8.1998; appl. 16.2.1998; D-prior. 18.2.1997).
- 141 Boehringer Ingelheim, WO 2007071743 (28.6.2007; D-prior. 20.12.2005).
- 142Roehrig, S. et al.: J. Med. Chem. (JMCMAR) 48, 5900-5908 (2005).
- 143 Bayer AG, WO 200 147 919 (5.7.2001; appl. 11.12.2000; D-prior. 24.12.1999).
- 144Pinto, D.J.P., et al. (2007) J. Med. Chem. 50, 5339.
- 145Pinto, D.J.P., et al. (2006) Bioorg. Med. Chem. 16, 4141–4147.
- 146 BMS, US 6413980 (2.7.2002; appl. 22.12.1999; USA-prior. 23.12.1998).
- 147Yoshikawa, K., et al. (2009) Bioorg. Med. Chem. 17, 8221.
- 148Haginoya, N., et al. (2004) J. Med. Chem. 47, 5167.
- 149 Daiichi Seiyaku, WO 0174774 (11.10.2001; appl. 5.4.2001; JP-prior. 5.4.2000).
- 150Zhang, P. (2009) Bioorg. Med. Chem. Lett. 19 (8), 2179–2185.
- 151 COR Therapeutics, US 6376515 (23.4.2002; appl. 28.2.2001; USA-prior. 29.2.2000).
- 152 Millenium Pharms., US 8524907 (3.9.2013; appl. 1.11.2007; USA-prior. 2.11.2006).
- 153 Portola Pharms., US 8946269 (3.2.2015; appl. 31.8.2011; USA-prior. 18.3.2011).
- 154Dalle, J.H., et al. (2016) Biol. Blood Marrow Transplant. 22 (3), 400–409.
- 155 Crinos Ind., US4693995 (15.9.1987; appl. 14.2.1985; IT-prior. 16.2.1984).
- 156Verges, J., et al. (2004) Proc. West. Pharmacol. Soc. 47, 50–53.
- 157Linhardt, R.J. (2003) J. Med. Chem. (JMCMAR) 46, 2551–2564.
- 158 Choay, US 4818816 (4.4.1989; F-prior. 28.4.1981).
- 159Jerebtsova, M., et al. (2007) Am. J. Physiol. Heart Circ. 292 (2), 743–750.
- 160Gabriel, S., et al. (1899) Ber. Dtsch. Chem. Ges. (BDCGAS) 32, 1266.
- 161Galat, A., et al. (1946) J. Am. Chem. Soc. (JACSAT) 68, 2729.
- 162 American Enka Corp., US 2453234 (1948; NL-prior. 1946).
- 163Einhorn, A. and Ladisch, C. (1900) Justus Liebigs Ann. Chem. (JLACBF) 310 (194).
- 164Levine, M. and Sedlecky, R. (1959) J. Org. Chem. (JOCEAH) 24, 115.
- 165 Daiichi Seiyaku, DAS 1443755 (appl. 23.12.1964; J-prior. 24.12.1963).
- 166Heidrich, R., et al. (1978) J. Neurol. 219 (1), 83–85.
- 167Kunitz, M., et al. (1936) J. Gen. Physiol. 19 (6), 991–1007.
- 168 Bayer AG, DE 2748295 (prior. 27.10.1977).
- 169 Bayer AG, DE 3339693 (15.5.1985; appl. 3.11.1983).
- 170Mahdy, A.M. (2004) Br. J. Anaesth. 93 (6), 842–858.
- 171Axelson, U., et al. (1965) Am. J. Human Genet. 17 (6), 466–472.
- 172Parr, D.G., et al. (2017) Drud Des. Devel. Ther. 11, 2149–2162.
- 173 Ono Pharmac., DOS 2 548 886 (appl. 31.10.1975; J-prior. 1.11.1974).
- 174 Ono Pharmac., US 4 021 472 (3.5.1977; J-prior. 1.11.1974).
- 175Fieser, L.F. (1939) J. Am. Chem. Soc. (JACSAT) 61, 2559, 3467.
- 176Hirschmann, R., et al. (1954) J. Am. Chem. Soc. (JACSAT) 76, 4592.
- 177Isler, O. and Doebel, K. (1939) Helv. Chim. Acta (HCACAV) 22, 945; (1954) 37, 225.
10.1002/hlca.193902201120 Google Scholar
- 178 Roche, (1943) US 2325681 (CH-prior. 1939).
- 179Fieser, L.F., et al. (1939) J. Am. Chem. Soc. (JACSAT) 61, 2559, 3216.
- 180 Velsicol, (1946) US 2402226 (appl. 1943).
- 181Acharya, S.S., et al. (2008) Haemophilia 114, 1151–1158.
- 182Shenoi, P.M. (1973) Proc. R. Soc. Med. 66 (2), 193–196.
- 183Oto, A., et al. (1999) Am. J. Roentgenol. 172 (6), 1481–1484.
- 184Demain, D.L., et al. (1954) Arch. Biochem. Biophys. 51 (1), 114–121.
- 185Stolz: Ber. Dtsch. Chem. Ges. (BDCGAS) 37, 4152 (1904).
- 186 Hoechst, (1903) DRP 152814.
- 187Crawley, J.T., et al. (2007) J. Thromb. Heamost. 5, 95–101.
- 188Singh, O., et al. (2011) J. Cutanous Aesth. Surg. 4 (1), 12–16.
- 189Szekalska, M., et al. (2016) Int. J. Polym. Sci. 769703.
- 190Tullar, B.F. (1948) J. Am. Chem. Soc. (JACSAT) 70, 2067.
- 191van der Besselaar, A.M., et al. (2010) Biologicals 38 (2), 430–436.
- 192Gilding, D.K., et al. (1979) Polymer 20 (12), 1559–1464.
- 193Coenen, M., et al. (2006) Equine Vet. J. Suppl. 36, 606–610.
- 194 Lab. OM S.A., GB 895 709 (appl. 31.12.1959; CH-prior. 28.1.1959).
- 195 Soc. Belge de 1'Azote et des Prod. Chim., (1950) US 2506294 (B-prior. 1943).
- 196 Labaz, GB 806908 (appl. 1957; USA-prior. 1956).
- 197 Pentapharm, US 3849252 (19.11.1974; CH-prior. 18.1.1971).
- 198 Pentapharm, DOS 2201993 (appl. 17.1.1972; CH-prior. 18.1.1971).
- 199Kuter, D.J., et al. (2008) Lancet 371 (9610), 395–404.
- 200 SmithKline Beecham, WO 0189457 (29.11.2001; appl. 24.5.2001; USA-prior. 25.5.2000).
- 201 SmithKline Beecham, WO 03098992 (4.12.2003; appl. 21.5.2003; USA-prior. 22.5.2002).
- 202Shima, M., et al. (2016) New Engl. J. Med. 374 (21), 2044–2053.
- 203 Shionogi, US 7601746 (13.10.2013; appl. 22.2.2007; JP-prior. 12.8.2003).
- 204Flick, A.C., et al. (2017) J. Med. Chem. 60, 6480–6515.
- 205 Astellas Pharma, US 7638536 (29.12.2009; appl. 15.1.2003; JP-prior. 18.1.2002).
- 206Hart, R., et al. (2015) Org. Process Res. Dev. 19, 537–542.
- 207 Rigel Pharms., WO 2005 012294 (10.2.2005; appl. 30.7.2004; USA-prior. 30.7.2003).